&lt;p&gt;Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study&lt;/p&gt;

Yang, Xinrong; Bai, Yanliang; Shi, Mingyue; Zhang, Wanjun; Niu, Junwei; Wu, Chang-Jing; Zhang, Lei; Xu, Zhiwei; Liu, Xiang; Chen, Yuqing; Sun, Kai

doi:10.2147/cmar.s237467

Cited by 8 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ELTS score could predict outcomes of CCyR, PFS, OS, and it was the only scoring system that could predict CML-related death. 17 Our study also provided positive evidence supporting the ELTS score as the most valuable risk stratification tool for CML-CP patients. Even if limited to F I G U R E 3 Cumulative incidence of chronic myeloid leukemia (CML)-related deaths stratified by the scoring systems, according to initial therapy.…”

Section: Discussionsupporting

confidence: 68%

“…Another recent study from China, which investigated patients treated with imatinib as first‐line therapy, presented the prognostic value of the ELTS score compared with the other three risk scores. ELTS score could predict outcomes of CCyR, PFS, OS, and it was the only scoring system that could predict CML‐related death 17 . Our study also provided positive evidence supporting the ELTS score as the most valuable risk stratification tool for CML‐CP patients.…”

Section: Discussionsupporting

confidence: 62%

See 1 more Smart Citation

The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort

et al. 2020

View full text Add to dashboard Cite

The European Treatment and Outcome Study (EUTOS) long‐term survival (ELTS) score predicts disease‐specific death in patients with chronic myeloid leukemia (CML) being treated with imatinib during the chronic phase (CP) of the disease. However, it is unclear whether the ELTS score predicts CML‐related events or treatment responses. This study evaluated the predictive value of the ELTS score regarding prognosis and treatment response in patients with CML‐CP. Clinical data were retrospectively obtained from patients enrolled in the CML Cooperative Study Group (CML‐CSG), which included patients diagnosed with CML‐CP from April 2001 to January 2016, and treated with any tyrosine kinase inhibitor (TKI) as first‐line therapy. Among 342 eligible patients, the ELTS scores indicated low‐, intermediate‐, and high‐risk in 74%, 21%, and 5% of patients, respectively. Patients with high ELTS scores had significantly higher disease‐specific mortality and worse event‐free survival, progression‐free survival, and overall survival. Among four risk scores, including the Sokal, Hasford, EUTOS, and ELTS scores, risk stratification by the ELTS score had the highest predictive value in assessing patient prognosis, and also in treatment responses. In fact, the EUTOS and ELTS scores were able to predict the major molecular response within 12 months. Most importantly, the ELTS score was the only scoring system that predicted deep molecular response at any time, regardless of risk level (65.0%, 43.7%, and 23.5% in low‐, intermediate‐, and high‐risk groups, respectively). Compared to other risk scores, the ELTS score was the most sensitive risk classification tool for the four endpoints of interest in this study, as well as molecular responses in patients with CML‐CP.

show abstract

Section: Discussionsupporting

confidence: 68%

Section: Discussionsupporting

confidence: 62%

The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort

et al. 2020

View full text Add to dashboard Cite

show abstract

“…13 Yang et al reported 5-year OS probabilities of 98% (95% confidence interval [CI]: 96-100%), 89% (95% CI: 83-95%) and 79% (95% CI: 78-91%) in the low-, intermediate-, and high-risk ELTS groups (p = 0.001 and 0.009 for high versus low and high versus intermediate risk groups). 14 Cortes et al reported two (3.2%) instances of QTc prolongation, whereas in our study group it is observed in four (9.7%) patients. 15 Saglio et al reported toxicity-related discontinuation rates of 5%.…”

Section: Discussioncontrasting

confidence: 76%

A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience

Singh

Kapoor

Mehta

et al. 2021

South Asian J Cancer

View full text Add to dashboard Cite

Context Nilotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). Aims We aim to evaluate the responses and safety of upfront Nilotinib therapy in Indian CML patients. Setting and Design We retrospectively reviewed the medical records of CML patients who received Nilotinib as an upfront treatment at our center between January 1, 2011 and October 15, 2019.The follow-up was taken till March 31, 2020. Results Forty One patients (n = 36 chronic phase and five accelerated-phase CML) received frontline Nilotinib. Median age was 39 years (21–63) with male-to-female ratio of 1.1: 1. At 3 months, 96.9% patients achieved BCR-ABL of ≤10% at international scale. By the end of 12 months, 71.5% patients achieved major molecular response (BCR-ABL ≤0.1%) and 91.4% patients achieved complete cytogenetic response assessed by BCR-ABL polymerase chain reaction of ≤1%. Common toxicities observed were weight gain, thrombocytopenia, corrected QT prolongation, and elevated serum amylase in 14 (34.1%), 7(17.07%), 4(9.7%), and 4(9.7%) patients, respectively. Overall, five patients had loss of response with further progression and death in three patients. At a median of 43.7 months, 38 patients survived with estimated 3 year event-free survival and overall survival of 65 ± 9 and 93 ± 5%. Conclusion This study showed remarkable good response with upfront Nilotinib in Indian patients with CML.

show abstract

“…While Yang et al observed the most distinct risk group discrimination of OS probabilities with the ELTS score in 462 imatinib-treated Chinese patients with a median follow-up of 69 months [25], Millot et al found that its three risk groups differed significantly from each other with respect to progression-free survival in 350 children with imatinib as first-line treatment-despite only 23 events (progression or death) [26]. In both studies, the authors concluded that the ELTS score outperformed all other scores [25,26]. However, instead of the conventional Sokal score, Millot et al considered the Sokal score for younger patients (≤45 years) [26,27].…”

Section: Discussionmentioning

confidence: 98%

“…The ELTS score has been validated several times for its ability to significantly discriminate risk groups regarding long-term survival outcome but mainly in patients first-line treated with imatinib [6,8,15,[24][25][26]28]. Despite significantly faster achievement of molecular reponses with second generation TKIs [10,13,[30][31][32][33], first-line treatment with imatinib and its generics is still widespread.…”

Section: Discussionmentioning

confidence: 99%

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

et al. 2020

View full text Add to dashboard Cite

Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.

show abstract

<p>Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study</p>

Cited by 8 publications

References 29 publications

The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort

The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort

A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Contact Info

Product

Resources

About